DONG-A ST CO.,LTD
Dong-A ST, spun off from Dong-A Socio Holdings in 2013 and KOSPI-listed, makes prescription drugs like Growtropin, Stillen, and Bacchus.
As of 2026-10-10, DONG-A ST CO.,LTD has 724 Korean MFDS device approvals, 202 Korean MFDS drug approvals, 99 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureDong-A ST was established in March 2013 through a spin-off from Dong-A Socio Holdings (formerly Dong-A Pharmaceutical) and listed on the KOSPI in April 2013 as a manufacturer and seller of prescription drugs, medical devices, and quasi-drugs. It manufactures and sells self-developed new drugs such as Stillen, Motilitone, Suganon, and Jublia, along with prescription drugs (ETC) including Growtropin and Gaster, produced at its Cheonan, Daegu, and Songdo campuses. In 2025, consolidated revenue reached approximately KRW 808.8 billion, up 15.9% year-on-year, with the prescription drug segment posting KRW 527.8 billion (up 19.0%) and overseas operations posting KRW 170.4 billion (up 12.8%).
Products & technology
- 그로트로핀Growth hormone treatment
- 모티리톤Functional dyspepsia treatment
- 슈가논Diabetes treatment
- 주블리아Onychomycosis (nail fungus) treatment
- 캔박카스Energy drink
- 스티렌Gastric mucosal protectant
- 가스터Peptic ulcer treatment
- 오팔몬Ischemic improvement agent
- 플라비톨Antithrombotic agent
- 리피논Hyperlipidemia treatment
- 바라클Hepatitis B treatment
- 이달비Hypertension treatment
- 자큐보GERD (gastroesophageal reflux disease) treatment
- 이뮬도사Stelara biosimilar for autoimmune disease
Regulatory approvals
data.go.kr202 Korean MFDS drug approvals · 1964–2026 / 724 Korean MFDS device approvals · 1998–2026
- MFDSSubsidiary: 동아참메드IVD reagents for blood coagulation factor test2026-08-18Product approval · Class 2체외 수인 26-4577 호
- MFDSSubsidiary: 동아참메드IVD reagents for blood coagulation factor test2026-08-18Product approval · Class 2체외 수인 26-4576 호
- MFDSSubsidiary: 동아참메드IVD reagents for blood coagulation factor test2026-08-18Product approval · Class 2체외 수인 26-4575 호
- MFDSSubsidiary: 동아참메드IVD reagents for blood coagulation factor test2026-08-18Product approval · Class 2체외 수인 26-4574 호
- MFDSSubsidiary: 동아참메드IVD reagents for blood coagulation factor test2026-08-18Product approval · Class 2체외 수인 26-4573 호
- MFDSSubsidiary: 동아참메드IVD reagents for blood coagulation factor test2026-08-18Product approval · Class 2체외 수인 26-4572 호
- MFDSSubsidiary: 동아참메드IVD reagents for blood coagulation factor test2026-08-18Product approval · Class 2체외 수인 26-4571 호
- MFDSSubsidiary: 동아참메드IVD reagents for blood coagulation factor test2026-08-18Product approval · Class 2체외 수인 26-4570 호
- MFDSSubsidiary: 동아참메드IVD reagents for blood coagulation factor test2026-08-18Product approval · Class 2체외 수인 26-4569 호
- MFDSSubsidiary: 동아참메드IVD reagents for blood coagulation factor test2026-08-18Product approval · Class 2체외 수인 26-4568 호
- MFDSSubsidiary: 동아참메드IVD reagents for blood coagulation factor test2026-08-18Product approval · Class 2체외 수인 26-4567 호
- MFDSSubsidiary: 동아참메드IVD reagents for blood coagulation factor test2026-08-18Product approval · Class 2체외 수인 26-4566 호
Show 68 more
- MFDSSubsidiary: 동아참메드IVD reagents for blood coagulation factor test2026-08-18Product approval · Class 2체외 수인 26-4565 호
- MFDSSubsidiary: 동아참메드IVD reagents for blood coagulation factor test2026-08-18Product approval · Class 2체외 수인 26-4564 호
- MFDSSubsidiary: 동아참메드IVD reagents for blood coagulation factor test2026-08-18Product approval · Class 2체외 수인 26-4563 호
- MFDSSubsidiary: 동아참메드IVD reagents for blood coagulation factor test2026-08-18Product approval · Class 2체외 수인 26-4562 호
- MFDSSubsidiary: 동아참메드IVD reagents for blood coagulation factor test2026-08-14Product approval · Class 2체외 수인 26-4559 호
- MFDSSubsidiary: 동아참메드IVD reagents for blood coagulation factor test2026-08-14Product approval · Class 2체외 수인 26-4558 호
- MFDSSubsidiary: 동아참메드IVD reagents for blood coagulation factor test2026-08-14Product approval · Class 2체외 수인 26-4557 호
- MFDSSubsidiary: 동아참메드IVD reagents for blood coagulation factor test2026-08-14Product approval · Class 2체외 수인 26-4556 호
- MFDSSubsidiary: 동아참메드IVD reagents for blood coagulation factor test2026-08-14Product approval · Class 2체외 수인 26-4555 호
- MFDSSubsidiary: 동아참메드IVD reagents for diagnostic blood coagulation test2026-08-11Product approval · Class 3체외 수허 26-183 호
- MFDSSubsidiary: 동아참메드IVD reagents for diagnostic blood coagulation test2026-08-11Product approval · Class 3체외 수허 26-182 호
- MFDSSubsidiary: 동아참메드IVD reagents for diagnostic blood coagulation test2026-08-11Product approval · Class 3체외 수허 26-181 호
- MFDSSubsidiary: 동아참메드IVD reagents for diagnostic blood coagulation test2026-08-11Product approval · Class 3체외 수허 26-180 호
- MFDSSubsidiary: 동아참메드IVD reagents for diagnostic blood coagulation test2026-08-11Product approval · Class 3체외 수허 26-179 호
- MFDSSubsidiary: 동아참메드IVD reagents for diagnostic blood coagulation test2026-08-11Product approval · Class 3체외 수허 26-178 호
- MFDSSubsidiary: 동아참메드IVD reagents for diagnostic blood coagulation test2026-08-11Product approval · Class 3체외 수허 26-177 호
- MFDSSubsidiary: 동아참메드IVD reagents for diagnostic blood coagulation test2026-08-11Product approval · Class 3체외 수허 26-176 호
- MFDSSubsidiary: 동아참메드IVD reagents for diagnostic blood coagulation test2026-08-11Product approval · Class 3체외 수허 26-175 호
- MFDSSubsidiary: 동아참메드IVD reagents for diagnostic blood coagulation test2026-08-11Product approval · Class 3체외 수허 26-174 호
- MFDSSubsidiary: 동아참메드IVD reagents for diagnostic blood coagulation test2026-08-11Product approval · Class 3체외 수허 26-173 호
- MFDSSubsidiary: 동아참메드Coagulation analyzer2026-07-31Product approval · Class 1체외 수신 26-1732 호
- MFDSSubsidiary: 동아참메드Coagulation analyzer2026-07-31Product approval · Class 1체외 수신 26-1731 호
- MFDS drugPitaEZ tablet 1/10mg(Pitavastatin calcium, Ezetimibe)2026-07-27Drug · Prescription · Approval202602167
- MFDSSubsidiary: 동아참메드Coagulation analyzer2026-07-23Product approval · Class 1체외 수신 26-1628 호
- MFDSSubsidiary: 동아참메드Coagulation analyzer2026-07-02Product approval · Class 1체외 수신 26-1465 호
- MFDSSubsidiary: 동아참메드Coagulation analyzer2026-06-29Product approval · Class 1체외 수신 26-1433 호
- MFDSSubsidiary: 동아참메드Laryngoscope, flexible, video2026-06-15Product approval · Class 2제인 26-4519 호
- MFDSSubsidiary: 동아참메드Immunoabsorbance analyzer2026-06-02Product approval · Class 1체외 수신 26-1198 호
- MFDSSubsidiary: 동아참메드Coagulation analyzer2026-05-20Product approval · Class 1체외 수신 26-1071 호
- MFDSSubsidiary: 동아참메드Coagulation analyzer2026-05-20Product approval · Class 1체외 수신 26-1070 호
- MFDSSubsidiary: 동아참메드Disinfecting unit, endoscope, flexible2026-04-08Product approval · Class 2제인 26-4314 호
- MFDSSubsidiary: 동아참메드System, medical image processing device2026-03-27Product approval · Class 1제신 26-367 호
- MFDSSubsidiary: 동아참메드Product name not recorded2026-02-13Product approval · Class 1신 26-23 호
- MFDSSubsidiary: 동아참메드Table, examination/treatment, ENT(ear/nose/throat)2026-02-10Product approval · Class 2제인 26-4135 호
- MFDSSubsidiary: 동아참메드Adaptor, endoscope element2025-12-23Product approval · Class 1수신 25-2810 호
- MFDS drugXcopri tablet(Cenobamate)2025-11-03Drug · Prescription · Approval202502834
- MFDSSubsidiary: 동아참메드IVD reagents for electrolyte tests2025-09-05Product approval · Class 2체외 수인 25-4520 호
- MFDSSubsidiary: 동아참메드Chair, examination/treatment, ENT(ear/nose/throat), electrically-powered2025-07-31Product approval · Class 2제인 25-4689 호
- MFDSSubsidiary: 동아참메드Other Reagents, classⅡ, for clinical chemistry2025-07-29Product approval · Class 2체외 수인 25-4429 호
- MFDSSubsidiary: 동아참메드Other Reagents, classⅡ, for clinical chemistry2025-07-11Product approval · Class 2체외 수인 25-4386 호
- MFDS drugEmpaproMet XR Tablet 12.5/1000mg (Empagliflozin, Metformin)2025-07-09Drug · Prescription · Approval202501721
- MFDS drugEmpaproMet XR Tablet 5/1000mg (Empagliflozin, Metformin)2025-07-09Drug · Prescription · Approval202501722
- MFDS drugEmpaproMet XR Tablet 25/1000mg (Empagliflozin, Metformin)2025-07-09Drug · Prescription · Approval202501723
- MFDS drugEmpaproMet XR Tablet 10/1000mg (Empagliflozin, Metformin)2025-07-09Drug · Prescription · Approval202501724
- MFDSSubsidiary: 동아참메드reagents for clinical enzymes2025-05-28Product approval · Class 2체외 수인 25-4303 호
- MFDS drugGemcit injection (solution) (Gemcitabine hydrochloride)2025-03-20Drug · Prescription · Approval202500640
- MFDSEndotherapy forceps, reusable2025-03-17Product approval · Class 1수신 25-507 호
- MFDSEndotherapy forceps, reusable2025-02-26Product approval · Class 1수신 25-401 호
- MFDSEndotherapy forceps, reusable2025-02-19Product approval · Class 1수신 25-336 호
- MFDSEndotherapy scissors, reusable2025-02-19Product approval · Class 1수신 25-334 호
- MFDScamera head for medical use2025-02-17Product approval · Class 1수신 25-304 호
- MFDS drugDutana tablet 0.5/5mg(Dutasteride, Tadalafil)2025-01-23Drug · Prescription · Approval202500183
- MFDSSubsidiary: 동아참메드camera head for medical use2024-11-04Product approval · Class 1제신 24-1349 호
- MFDSSubsidiary: 동아참메드Table, examination/treatment, ENT(ear/nose/throat)2024-08-08Product approval · Class 2제인 24-763 호
- MFDSSubsidiary: 동아참메드Chemiluminescence assay(CLIA) analyzer2024-07-30Product approval · Class 1체외 수신 24-1411 호
- MFDS drugSugamet XR tablet 2.5/850mg (for export)2024-07-26Drug · Prescription · Approval202401806
- MFDSSubsidiary: 동아참메드Chair, examination/treatment, ENT(ear/nose/throat), electrically-powered2024-06-24Product approval · Class 2제인 24-615 호
- MFDS drugOtelia tablet(Apremilast)2024-04-17Drug · Prescription · Approval202400868
- MFDSSubsidiary: 동아참메드Other Reagents, classⅡ, for clinical chemistry2024-03-07Product approval · Class 2체외 수인 24-102 호
- MFDS drugGrowtropin-II injection (solution) i pen (Somatropin)2023-11-24Drug · Prescription · Approval202303218
- MFDS drugSugatri XR tablet 5/10/1000mg(Evogliptin,Dapagliflozin,Metformin hydrochloride)2023-10-30Drug · Prescription · Approval202303029
- MFDSSubsidiary: 동아참메드Disinfecting unit, endoscope, flexible2023-08-18Product approval · Class 2제인 23-5027 호
- MFDSSubsidiary: 동아참메드Disinfecting unit, endoscope, flexible2023-08-18Product approval · Class 2제인 23-5026 호
- MFDS drugSugadapa Tablet2023-03-10Drug · Prescription · Approval202300827
- MFDSSubsidiary: 동아참메드System, medical image processing device2023-03-07Product approval · Class 1제신 23-356 호
- MFDSSubsidiary: 동아참메드System, medical image processing device2023-03-07Product approval · Class 1제신 23-355 호
- MFDSSubsidiary: 동아참메드Camera, still, endoscopic2023-02-28Product approval · Class 2제인 23-4212 호
- MFDSSubsidiary: 동아참메드Camera, still, endoscopic2023-02-28Product approval · Class 2제인 23-4210 호
Showing the 80 most recent of 926 records.
Clinical trials
data.go.kr98 MFDS clinical trial authorisations · 2012–2026 (Phase 1 46 · Bioequivalence 25 · Phase 3 15 · Phase 2 4 · Phase 1/2a 2)
- Phase 1DA-52232026-05-27
2 trial sites
- Phase 1DA-52272026-05-26
2 trial sites
- BioequivalenceDA-52302025-12-30
2 trial sites
- Bioequivalence슈가메트서방정2.5/850밀리그램2025-11-10
2 trial sites
- Bioequivalence슈가메트서방정2.5/850밀리그램2025-11-10
2 trial sites
- Phase 1/2aDA-35012025-10-27
3 trial sites
- Phase 2aDA-28112025-09-18
26 trial sites
- BioequivalenceDA-29022025-08-19
2 trial sites
- Phase 1DA-52222025-06-10
2 trial sites
- Phase 1DA-52172025-06-02
2 trial sites
- Phase 1DA-52232025-04-30
2 trial sites
- Phase 1DA-52232025-04-30
2 trial sites
Show 68 more
- Phase 1DA-52222025-03-21
2 trial sites
- Phase 1DA-52222025-03-21
2 trial sites
- Phase 1DA-5221_012024-08-09
2 trial sites
- Phase 1DA-75032024-04-15
3 trial sites
- Phase 3DA-52212023-11-29
28 trial sites
- Phase 1/2aDA-45052023-11-24
3 trial sites
- Phase 3DA-52192023-10-25
26 trial sites
- Phase 1DA-80102023-06-22
2 trial sites
- Phase 1DA-80102023-06-22
2 trial sites
- Phase 3DA-52122023-03-20
22 trial sites
- Phase 1DA-80102023-02-27
2 trial sites
- Bioequivalence슈가메트서방정5/1000밀리그램2022-12-09
2 trial sites
- Bioequivalence슈가메트서방정2.5/500밀리그램2022-12-06
2 trial sites
- Bioequivalence슈가메트서방정2.5/500밀리그램2022-11-11
2 trial sites
- Bioequivalence슈가메트서방정5/1000밀리그램2022-11-11
2 trial sites
- Phase 1DA-52182022-06-15
2 trial sites
- Phase 1DA-52162022-06-09
2 trial sites
- BioequivalenceDA-52152022-03-25
2 trial sites
- Phase 3DA-80102022-01-18
24 trial sites
- Phase 1bDA-52072021-10-27
4 trial sites
- Phase 1DA-52112021-10-20
2 trial sites
- BioequivalenceDA-5213 10mg2021-09-07
2 trial sites
- BioequivalenceDA-5210 10/500mg2021-09-07
2 trial sites
- BioequivalenceDA-5210 10/500mg2021-09-07
2 trial sites
- BioequivalenceDA-5210 10/1000mg2021-09-07
2 trial sites
- BioequivalenceDA-5210 10/1000mg2021-09-06
2 trial sites
- Phase 1DA-28112021-06-09
2 trial sites
- Phase 1DA-28032021-05-25
2 trial sites
- Phase 1DA-80102020-11-03
2 trial sites
- BioequivalenceDA-52092020-10-06
2 trial sites
- Phase 1bDA-52072020-06-11
2 trial sites
- Phase 1DA-28112020-04-16
2 trial sites
- Bioequivalence동아아토르바스타틴정80밀리그램(아토르바스타틴칼슘삼수화물)2020-02-11
2 trial sites
- Phase 3슈가논정5밀리그램(에보글립틴타르타르산염)2020-02-07
11 trial sites
- Phase 3슈가논정5밀리그램(에보글립틴타르타르산염)2019-08-29
15 trial sites
- Bioequivalence가스터디정20㎎(파모티딘)2019-08-23
2 trial sites
- Phase 1슈가논정5밀리그램(에보글립틴타르타르산염)2019-07-16
1 trial site
- Phase 2DA-12292019-06-24
11 trial sites
- Phase 1DA-52072019-03-25
1 trial site
- Bioequivalence슈가메트서방정5/1000밀리그램2019-01-25
2 trial sites
- Bioequivalence슈가메트서방정5/1000밀리그램2019-01-25
2 trial sites
- Phase 1슈가논정5밀리그램(에보글립틴타르타르산염)2018-08-24
1 trial site
- Phase 2bDA-80102018-05-09
12 trial sites
- Phase 1DA-52062016-11-23
1 trial site
- Bioequivalence슈가메트서방정2.5/500밀리그램2016-10-28
2 trial sites
- Phase 2DA-4001C2016-10-13
2 trial sites
- Phase 3DA28022016-09-02
25 trial sites
- Bioequivalence바소트롤에스알정64밀리그램(카르베딜롤)2016-08-17
2 trial sites
- Bioequivalence슈가메트서방정5/1000밀리그램2016-07-21
2 trial sites
- Phase 1DA-3031주(프리필드시린지)2016-04-07
1 trial site
- Phase 1카티스템 (동종 제대혈유래 중간엽줄기세포)2016-03-29
1 trial site
- Phase 1DA-4001C2016-03-18
1 trial site
- Phase 1슈가논정5밀리그램(에보글립틴타르타르산염)2016-01-19
1 trial site
- Phase 1슈가논정5밀리그램(에보글립틴타르타르산염)2016-01-15
1 trial site
- Phase 1DA-30302015-12-31
1 trial site
- Phase 3DA-30022015-12-04
11 trial sites
- Phase 1슈가논정5밀리그램(에보글립틴타르타르산염)2015-11-25
2 trial sites
- Phase 1DA-32852015-10-29
1 trial site
- Phase 1DA-28022015-08-12
1 trial site
- Phase 1DA-1229_012015-02-27
1 trial site
- Phase 1슈가논정5밀리그램(에보글립틴타르타르산염)2014-07-17
1 trial site
- Phase 3글리닙필름코팅정100밀리그램, 글리닙필름코팅정200밀리그램, 글리닙필름코팅정400밀리그램(이매티닙메실산염)2014-06-02
13 trial sites
- Bioequivalence세레콕시브2014-05-28
2 trial sites
- BioequivalenceTerizidone2014-05-26
2 trial sites
- Phase 1DA-1229_012014-04-25
1 trial site
- Phase 3DA-81592014-04-07
9 trial sites
- Phase 1슈가논정5밀리그램(에보글립틴타르타르산염)2014-02-05
1 trial site
- Phase 1DA-7218(TR-701)2014-01-16
1 trial site
Showing the 80 most recent of 98 records.
Global clinical trials
ClinicalTrials.gov · sponsor-matchedPhase 4 · Recruiting · 2026-08 · NCT07686679
Phase 1 · Completed · 2026-06 · NCT07633691
Phase 1 · Recruiting · 2026-05 · NCT07481357
Phase 1 · Completed · 2026-05 · NCT07513649
Phase 1 · Completed · 2026-01 · NCT07342062
Phase 1 · Completed · 2025-12 · NCT07297940
Phase 1 · Completed · 2025-11 · NCT07239453
Phase 2 · Not yet recruiting · 2025-11 · NCT07239440
Phase 1 · Withdrawn · 2025-11 · NCT07007520
Phase 4 · Not yet recruiting · 2025-11 · NCT07229534
Show 112 more trials
Phase 1 · Completed · 2025-07 · NCT07027982
Phase 1 · Completed · 2025-07 · NCT07046715
Phase 1 · Completed · 2025-07 · NCT07007533
Phase 1 · Not yet recruiting · 2025-06 · NCT06993181
Phase 1 · Not yet recruiting · 2025-05 · NCT06993168
Phase 1 · Unknown · 2024-09 · NCT06616883
Completed · 2024-08 · NCT06654856
Phase 1 · Completed · 2024-05 · NCT06391827
Phase 1/2 · Recruiting · 2024-04 · NCT06293651
Phase 3 · Active not recruiting · 2024-04 · NCT06290349
Phase 3 · Completed · 2024-01 · NCT06151210
Phase 1 · Completed · 2023-08 · NCT05992428
Phase 1 · Completed · 2023-08 · NCT05991401
Phase 3 · Completed · 2023-06 · NCT05842408
Phase 1 · Completed · 2023-05 · NCT05812417
Phase 4 · Completed · 2023-04 · NCT05743907
Phase 1 · Unknown · 2023-03 · NCT05739916
Phase 1 · Unknown · 2023-03 · NCT05739903
Phase 4 · Completed · 2023-03 · NCT05957380
Phase 1 · Unknown · 2023-03 · NCT05739851
Phase 1 · Unknown · 2023-03 · NCT05739877
- Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women
Phase 4 · Completed · 2023-01 · NCT05630768
Phase 1 · Unknown · 2022-08 · NCT05506007
Phase 1 · Unknown · 2022-07 · NCT05449704
Phase 3 · Completed · 2022-05 · NCT05282069
Phase 1 · Unknown · 2022-05 · NCT05376085
Phase 1 · Completed · 2021-12 · NCT05106205
Phase 1 · Completed · 2021-12 · NCT05132049
Phase 1 · Completed · 2021-11 · NCT05127746
Phase 1 · Completed · 2021-11 · NCT05098886
Phase 1 · Completed · 2021-10 · NCT05098262
Phase 1 · Completed · 2021-10 · NCT05108571
Phase 1 · Completed · 2021-10 · NCT05098275
Phase 1 · Completed · 2021-07 · NCT04906109
Phase 1 · Completed · 2021-07 · NCT04938752
Phase 3 · Completed · 2021-04 · NCT04785326
Recruiting · 2021-02 · NCT04798690
Phase 1 · Completed · 2021-01 · NCT04686825
Phase 4 · Unknown · 2020-12 · NCT04653779
Phase 1 · Completed · 2020-11 · NCT04671316
Phase 1 · Completed · 2020-08 · NCT04473417
Phase 1 · Unknown · 2020-07 · NCT04479865
- The Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of Evogliptin in Hemodialysis Patients
Phase 1 · Completed · 2020-07 · NCT04195919
Phase 3 · Completed · 2020-05 · NCT04356742
Phase 1 · Unknown · 2020-03 · NCT04325009
Unknown · 2020-03 · NCT04326166
Phase 3 · Completed · 2020-01 · NCT04170998
Unknown · 2019-10 · NCT04123899
Phase 2 · Completed · 2019-08 · NCT04055883
Phase 1 · Completed · 2019-06 · NCT04013477
Completed · 2019-04 · NCT03932435
Phase 4 · Completed · 2019-04 · NCT03910361
Phase 1 · Completed · 2019-02 · NCT03944200
Phase 1 · Completed · 2019-02 · NCT03939143
Phase 1 · Completed · 2018-11 · NCT03766724
Phase 1 · Completed · 2018-08 · NCT03646721
Phase 2 · Completed · 2018-07 · NCT03566134
Phase 2 · Completed · 2018-02 · NCT03189563
Phase 4 · Completed · 2017-11 · NCT03280927
Phase 1 · Completed · 2017-05 · NCT03200496
Phase 1 · Completed · 2017-03 · NCT03061981
Phase 3 · Completed · 2017-03 · NCT02967939
Phase 3 · Completed · 2017-01 · NCT03343145
Phase 1 · Completed · 2016-11 · NCT02954822
Phase 1 · Completed · 2016-10 · NCT02963389
Phase 1 · Completed · 2016-09 · NCT02754219
Phase 4 · Completed · 2016-09 · NCT02974504
Phase 1 · Completed · 2016-07 · NCT02753803
Phase 1 · Completed · 2016-07 · NCT02824380
Phase 1 · Unknown · 2016-06 · NCT02821312
Phase 4 · Completed · 2016-04 · NCT02955706
Phase 3 · Unknown · 2016-03 · NCT03521713
Phase 3 · Completed · 2016-02 · NCT02770157
Phase 1 · Completed · 2016-02 · NCT02725086
Phase 4 · Completed · 2015-11 · NCT02780323
Phase 1 · Unknown · 2015-11 · NCT02580006
Phase 1 · Completed · 2015-10 · NCT02557594
Phase 2 · Completed · 2015-06 · NCT02365701
Phase 1 · Completed · 2015-04 · NCT02375139
Phase 4 · Completed · 2015-03 · NCT02433119
Phase 2 · Completed · 2014-12 · NCT02554240
Phase 4 · Terminated · 2014-10 · NCT02204722
Phase 4 · Completed · 2014-09 · NCT02280590
Phase 1 · Unknown · 2014-09 · NCT02267902
Phase 1 · Completed · 2014-08 · NCT02241200
Phase 1 · Completed · 2014-07 · NCT02167061
Phase 1 · Completed · 2014-07 · NCT02214693
Phase 1 · Completed · 2014-05 · NCT02097043
Phase 2/3 · Completed · 2014-04 · NCT02304198
Phase 3 · Unknown · 2014-04 · NCT02282670
Phase 1/2 · Completed · 2014-01 · NCT02280603
Phase 4 · Completed · 2013-09 · NCT01913431
Phase 3 · Completed · 2013-07 · NCT02946541
Phase 3 · Completed · 2013-05 · NCT02949193
Phase 3 · Completed · 2013-02 · NCT01813630
Phase 4 · Completed · 2012-10 · NCT01817556
Phase 4 · Completed · 2012-09 · NCT01912066
Phase 1 · Completed · 2012-08 · NCT01633723
Phase 4 · Completed · 2012-08 · NCT01817465
Phase 1 · Completed · 2012-05 · NCT01751919
Phase 2 · Completed · 2012-04 · NCT01670357
Phase 3 · Completed · 2012-02 · NCT01674855
Phase 3 · Completed · 2012-02 · NCT01786902
Phase 2 · Completed · 2011-11 · NCT01813799
Phase 1 · Completed · 2011-09 · NCT01526122
Phase 2 · Completed · 2011-08 · NCT01553721
Phase 2 · Completed · 2010-07 · NCT01923545
Phase 1 · Completed · 2009-09 · NCT00967772
Phase 1 · Completed · 2008-09 · NCT01162954
Phase 3 · Completed · 2007-01 · NCT01820728
Phase 2 · Completed · 1997-03 · NCT07139886
Phase 1 · Completed · NCT00959777
R&D and key agreements
Source: DART corporate disclosure대사질환치료제 신약 개발 · 당뇨, 비만, MASH · Continuing investment to strengthen R&D competitiveness in metabolic disease drug development.
Key disclosures
KRX KIND via OpenDARTPublications
PubMed · affiliation-matched- Gremlin-2 inhibits hepatocellular carcinoma progression by suppressing Akt/MEK-RPL23 signaling pathway.
Genes & diseases · 2026-11 · Lim D, Park J, Gil W 외 7
- Exploring the Antitubercular, Antimicrobial Potency, ADME-T Calculations and Docking Studies of 1,2,4-Triazole-Bearing Benzimidazoles.
Chemistry & biodiversity · 2026-08 · Shaik KM, Pandurangan K, Bhoomandla S 외 2
- Stabilization strategies and advancements in lyophilization to preserve integrity and efficacy of next-generation biologicals.
International journal of pharmaceutics: X · 2026-06 · Maharjan R, Shin CY, Lee SK 외 7
- Toxin dimerization and a distinct DNA-binding architecture define chromosomal Phd-Doc regulation.
Nucleic acids research · 2026-03 · Park JY, Kim M, Lim B 외 1
- Clinical CYP2D6-Mediated Pharmacokinetic Drug-Drug Interactions of DA-8010 with Paroxetine or Mirabegron in Healthy Korean Participants.
Drug design, development and therapy · 2026-01 · Ryu H, Cho JY, Lee DY 외 1
- Pharmacokinetic Drug-Drug Interactions of DA-8010 with Clarithromycin or Rifampicin: Influence of CYP2D6 Phenotype on the Extent of These Interactions.
Drug design, development and therapy · 2026-01 · Lee S, Won H, Yu KS 외 2
- Preclinical Pharmacological and Toxicological Evaluation of SB5794, a Novel Aryl Hydrocarbon Receptor Modulator on the Kynurenine-AhR Axis.
Biomolecules & therapeutics · 2026-01 · Cha D, Choi SJ, Park H 외 6
- MHY498 Nanosuspensions for Improved Topical Drug Delivery: Understanding of Its Solubility Behavior in DEGME + Water Mixtures and Preparation of Nanosuspension Using Box-Behnken Design.
Pharmaceutics · 2026-01 · Ha ES, Lee HN, Lee SK 외 6
- LC-MS/MS Assay for Quantification of DA-1241, a Novel GPR119 Agonist, in Animal and Human Plasma: Application to Preclinical Pharmacokinetic Studies.
Journal of mass spectrometry : JMS · 2025-12 · Kim SJ, Bang WS, Li Z 외 3
- Hydrogen sulfide induces regulatory B cells via glycolysis and mitochondrial ROS, attenuating LPS-induced lung injury.
Cell communication and signaling : CCS · 2025-10 · Jeong YS, Park B, Lee M 외 4
Show 89 more publications
- Development of pH-Sensitive Multiparticulates for Orally Disintegrating Tablets of Proton Pump Inhibitors: Physicochemical Characterization and Drug Release Studies.
Pharmaceutics · 2025-09 · Singh M, Ullapu PR, Mariadoss AVA 외 2
- Design of Electrostatic Nanocomplex of Semaglutide with Protamine and Zinc for Subcutaneous Prolonged Delivery.
Nanomaterials (Basel, Switzerland) · 2025-09 · Yang IG, Kim JS, Kang MJ
- Determination of absolute bioavailability, absorption, metabolism, and excretion of evogliptin in healthy male subjects using a microtracer method.
Journal of pharmaceutical sciences · 2025-08 · Lee DY, Kang HE
- Mouse Tumor Tissue-Derived Extracellular Vesicles Induce Angiogenesis Through VEGF Production From Macrophages.
Journal of extracellular vesicles · 2025-08 · Yoon YJ, Bae S, Choi EJ 외 8
- Gremlin-2 is a novel tumor suppressor that negatively regulates ID1 in breast cancer.
Breast cancer research : BCR · 2024-11 · Jung J, Kim NH, Park J 외 11
- MiR-140-3p Improves Sensitivity to Docetaxel by Suppressing PD-L1/ABCG2/MVP Expression in Lung Adenocarcinoma.
Anticancer research · 2024-10 · Kwon M, Lim D, Park J 외 9
- Discovery of A-910, a Highly Potent and Orally Bioavailable Dual MerTK/Axl-Selective Tyrosine Kinase Inhibitor.
Journal of medicinal chemistry · 2024-10 · Yu Y, Jang M, Miyashiro J 외 33
- Mechanism of Methylene Blue Inducing the Disulfide Bond Formation of Tubulin-Associated Unit Proteins.
JACS Au · 2024-07 · Seo DH, Huh YH, Cheong HK 외 5
- Electroreductive Access to 1,2-Aminoalcohols via Cross Aza-Pinacol Coupling of N-Acyl Diarylketimines and Aldehydes.
Organic letters · 2024-04 · Kwak D, Jung S, Ha H 외 4
- Evaluation of Food Effect on the Pharmacokinetics of Velufenacin, a New Muscarinic Receptor Antagonist, in Healthy Subjects.
Clinical pharmacology in drug development · 2024-02 · Khwarg J, Chung WK, Lee S 외 7
- Preparation of Hot-Melt-Extruded Solid Dispersion Based on Pre-Formulation Strategies and Its Enhanced Therapeutic Efficacy.
Pharmaceutics · 2023-11 · Lee SK, Ha ES, Park H 외 5
- The inhibitory effect of Gremlin-2 on adipogenesis suppresses breast cancer cell growth and metastasis.
Breast cancer research : BCR · 2023-10 · Jung J, Kim NH, Kwon M 외 6
- GPR119 activation by DA-1241 alleviates hepatic and systemic inflammation in MASH mice through inhibition of NFκB signaling.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023-10 · Lee SH, Park H, Yang EK 외 6
- Pharmacokinetics of the novel 5-HT4 receptor agonist, DA-6886, in dogs.
Xenobiotica; the fate of foreign compounds in biological systems · 2023-05 · Lee DY, Kang HE
- Injectable sustained-release poly(lactic-co-glycolic acid) (PLGA) microspheres of exenatide prepared by supercritical fluid extraction of emulsion process based on a design of experiment approach.
Bioengineering & translational medicine · 2023-05 · Park H, Ha ES, Kim JS 외 1
- Safety, tolerability, and pharmacokinetics of single and multiple ascending Oral doses of DA-8010 in healthy subjects: First-in-human phase I study.
Pharmacology research & perspectives · 2023-02 · Lee DY, Lee MJ, Ryu C 외 2
- Diesel exhaust particle exposure accelerates oxidative DNA damage and cytotoxicity in normal human bronchial epithelial cells through PD-L1.
Environmental pollution (Barking, Essex : 1987) · 2023-01 · Kwon M, Jung J, Park HS 외 10
- A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects.
Drug design, development and therapy · 2023-01 · Kim HC, Lee S, Sung S 외 3
- Active coating of immediate-release evogliptin tartrate to prepare fixed dose combination tablet with sustained-release metformin HCl.
International journal of pharmaceutics · 2022-07 · Han Won D, Park H, Seo JW 외 3
- ERβ Isoforms Have Differential Clinical Significance in Breast Cancer Subtypes and Subgroups.
Current issues in molecular biology · 2022-04 · Choi Y, Kim H, Pollack S
- Pharmacokinetics of DA-6886, A New 5-HT4 Receptor Agonist, in Rats.
Pharmaceutics · 2022-03 · Lee DY, Kang HE
- Preparation and Characterization of Fenofibrate Microparticles with Surface-Active Additives: Application of a Supercritical Fluid-Assisted Spray-Drying Process.
Pharmaceutics · 2021-12 · Kim JS, Park H, Ha ES 외 3
- A novel GPR119 agonist DA-1241 preserves pancreatic function via the suppression of ER stress and increased PDX1 expression.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021-12 · Kim MK, Cheong YH, Lee SH 외 8
- Pharmaceutical Applications of Supercritical Fluid Extraction of Emulsions for Micro-/Nanoparticle Formation.
Pharmaceutics · 2021-11 · Park H, Kim JS, Kim S 외 3
- Optimization of bilayer tablet manufacturing process for fixed dose combination of sustained release high-dose drug and immediate release low-dose drug based on quality by design (QbD).
International journal of pharmaceutics · 2021-08 · Won DH, Park H, Ha ES 외 3
- Development and Validation of an LC-MS/MS Method for Quantification of the Novel Antibacterial Candidate DA-7010 in Plasma and Application to a Preclinical Pharmacokinetic Study.
Pharmaceuticals (Basel, Switzerland) · 2021-02 · Kwon MH, Lee DY, Kang HE
- Protein Loading into Spongelike PLGA Microspheres.
Pharmaceutics · 2021-01 · Kim Y, Sah H
- Pharmacokinetics, Tolerability and Pharmacogenetics of DA-8031 After Multiple Ascending Doses in Healthy Male Subjects.
Drug design, development and therapy · 2021-01 · Hwang S, Lee DY, Cho JY 외 4
- Evogliptin, a dipeptidyl peptidase-4 inhibitor, attenuates pathological retinal angiogenesis by suppressing vascular endothelial growth factor-induced Arf6 activation.
Experimental & molecular medicine · 2020-10 · Seo S, Kim MK, Kim RI 외 3
- Characterization and therapeutic efficacy evaluation of glimepiride and L-arginine co-amorphous formulation prepared by supercritical antisolvent process: Influence of molar ratio and preparation methods.
International journal of pharmaceutics · 2020-05 · Park H, Jin Seo H, Hong SH 외 6
- Preparation and characterization of glimepiride eutectic mixture with l-arginine for improvement of dissolution rate.
International journal of pharmaceutics · 2020-05 · Park H, Seo HJ, Ha ES 외 4
- Pharmaceutical Characterization and In Vivo Evaluation of Orlistat Formulations Prepared by the Supercritical Melt-Adsorption Method Using Carbon Dioxide: Effects of Mesoporous Silica Type.
Pharmaceutics · 2020-04 · Park H, Cha KH, Hong SH 외 7
- Pharmacokinetic Study of a Soft Gelatin Capsule and a Solid-Supersaturatable SMEDDS Tablet of Dutasteride in Beagle Dogs.
European journal of drug metabolism and pharmacokinetics · 2020-04 · Kim JS, Ha ES, Park H 외 3
- Pathological manifestation of the induced pluripotent stem cell-derived cortical neurons from an early-onset Alzheimer's disease patient carrying a presenilin-1 mutation (S170F).
Cell proliferation · 2020-04 · Li L, Kim HJ, Roh JH 외 11
- Melt Amorphisation of Orlistat with Mesoporous Silica Using a Supercritical Carbon Dioxide: Effects of Pressure, Temperature, and Drug Loading Ratio and Comparison with Other Conventional Amorphisation Methods.
Pharmaceutics · 2020-04 · Park H, Cha KH, Hong SH 외 5
- Effect of Formulation Factors and Oxygen Levels on the Stability of Aqueous Injectable Solution Containing Pemetrexed.
Pharmaceutics · 2020-01 · Won DH, Park H, Ha ES 외 4
- Development of a Resveratrol Nanosuspension Using the Antisolvent Precipitation Method without Solvent Removal, Based on a Quality by Design (QbD) Approach.
Pharmaceutics · 2019-12 · Kuk DH, Ha ES, Ha DH 외 11
- Efficacy of evogliptin and cenicriviroc against nonalcoholic steatohepatitis in mice: a comparative study.
The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2019-11 · Wang Z, Park H, Bae EJ
- Effect of Stabilizers on Encapsulation Efficiency and Release Behavior of Exenatide-Loaded PLGA Microsphere Prepared by the W/O/W Solvent Evaporation Method.
Pharmaceutics · 2019-11 · Park H, Ha DH, Ha ES 외 3
- Preparation and Evaluation of Resveratrol-Loaded Composite Nanoparticles Using a Supercritical Fluid Technology for Enhanced Oral and Skin Delivery.
Antioxidants (Basel, Switzerland) · 2019-11 · Ha ES, Sim WY, Lee SK 외 7
- The First Generation of iPSC Line from a Korean Alzheimer's Disease Patient Carrying APP-V715M Mutation Exhibits a Distinct Mitochondrial Dysfunction.
Experimental neurobiology · 2019-06 · Li L, Roh JH, Kim HJ 외 9
- Pharmacological characterization of DA-8010, a novel muscarinic receptor antagonist selective for urinary bladder over salivary gland.
European journal of pharmacology · 2019-01 · Lee MJ, Moon JH, Lee HK 외 3
- Analytical method development of methylisothiazolinone, a preservative, in rat plasma using LC-MS/MS.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2018-11 · Kim HY, Lee YJ, Kim KB
- Enhanced Bioavailability of Tadalafil after Intranasal Administration in Beagle Dogs.
Pharmaceutics · 2018-10 · Kim JS, Kim MS, Baek IH
- Pharmacokinetics and Brain Distribution of the Active Components of DA-9805, Saikosaponin A, Paeonol, and Imperatorin in Rats.
Pharmaceutics · 2018-08 · Kwon MH, Jeong JS, Ryu J 외 2
- Additive effects of evogliptin in combination with pioglitazone on fasting glucose control through direct and indirect hepatic effects in diabetic mice.
European journal of pharmacology · 2018-07 · Kim TH, Lee JH, Chae YN 외 2
- Effects of Renal Impairment on the Pharmacokinetics and Safety of Udenafil.
Journal of clinical pharmacology · 2018-07 · Cho YS, Noh YH, Lim HS 외 10
- Recombinant growth hormone therapy for prepubertal children with idiopathic short stature in Korea: a phase III randomized trial.
Journal of endocrinological investigation · 2018-04 · Kim J, Suh BK, Ko CW 외 11
- Novel botanical drug DA-9803 prevents deficits in Alzheimer's mouse models.
Alzheimer's research & therapy · 2018-01 · Pagnier GJ, Kastanenka KV, Sohn M 외 4
- Comparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers.
Drug design, development and therapy · 2018-01 · Choi C, Yoo BW, Kim CO 외 5
- Efficacy and safety of evogliptin monotherapy in patients with type 2 diabetes and moderately elevated glycated haemoglobin levels after diet and exercise.
Diabetes, obesity & metabolism · 2017-12 · Park J, Park SW, Yoon KH 외 12
- Effects of clarithromycin on the pharmacokinetics of evogliptin in healthy volunteers.
Journal of clinical pharmacy and therapeutics · 2017-12 · Oh ES, Choi C, Kim CO 외 4
- Simultaneous determination of saikosaponin a, paeonol, and imperatorin, components of DA-9805, in rat plasma by LC-MS/MS and application to a pharmacokinetic study.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2017-11 · Kwon MH, Jeong JS, Ryu J 외 2
- Ionotropic Receptor 76b Is Required for Gustatory Aversion to Excessive Na+ in Drosophila.
Molecules and cells · 2017-10 · Lee MJ, Sung HY, Jo H 외 4
- Pharmacokinetics, Safety, and Tolerability of Tedizolid Phosphate After Single-dose Administration in Healthy Korean Male Subjects.
Clinical therapeutics · 2017-09 · Kim Y, Kim A, Lee S 외 6
- Efficacy and safety of adding evogliptin versus sitagliptin for metformin-treated patients with type 2 diabetes: A 24-week randomized, controlled trial with open label extension.
Diabetes, obesity & metabolism · 2017-05 · Hong SM, Park CY, Hwang DM 외 7
- Combined Application of UHPLC-QTOF/MS, HPLC-ELSD and 1 H-NMR Spectroscopy for Quality Assessment of DA-9801, A Standardised Dioscorea Extract.
Phytochemical analysis : PCA · 2017-05 · Kang KB, Ryu J, Cho Y 외 3
- A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2017-02 · Park KH, Lee S, Park JH 외 11
- Anti-Neurodegenerative Biflavonoid Glycosides from Impatiens balsamina.
Journal of natural products · 2017-02 · Kim CS, Bae M, Oh J 외 8
- Effects of renal impairment on the pharmacokinetics and pharmacodynamics of a novel dipeptidyl peptidase-4 inhibitor, evogliptin (DA-1229).
Diabetes, obesity & metabolism · 2017-02 · Oh J, Kim AH, Lee S 외 7
- Facilitated saliva secretion and reduced oral inflammation by a novel artificial saliva system in the treatment of salivary hypofunction.
Drug design, development and therapy · 2017-01 · Kang M, Park H, Jun JH 외 2
- Pharmacokinetics and tolerability of DA-8031, a novel selective serotonin reuptake inhibitor for premature ejaculation in healthy male subjects.
Drug design, development and therapy · 2017-01 · Shin D, Lee S, Yi S 외 5
- Anticancer Efficacy of Cordyceps militaris Ethanol Extract in a Xenografted Leukemia Model.
Evidence-based complementary and alternative medicine : eCAM · 2017-01 · Park JG, Son YJ, Lee TH 외 8
- Preferential use of minor codons in the translation initiation region of human genes.
Human genetics · 2017-01 · Park JH, Kwon M, Yamaguchi Y 외 5
- A comparative pharmacokinetic and tolerability analysis of the novel orotic acid salt form of tenofovir disoproxil and the fumaric acid salt form in healthy subjects.
Drug design, development and therapy · 2017-01 · Kim YK, Choi MJ, Oh TY 외 2
- Comparable pharmacokinetics and pharmacodynamics of two epoetin alfa formulations Eporon® and Eprex® following a single subcutaneous administration in healthy male volunteers.
Drug design, development and therapy · 2017-01 · Yoon S, Rhee SJ, Heo SJ 외 5
- The Effect of Age on the Pharmacokinetics of Udenafil in Healthy Subjects.
Journal of clinical pharmacology · 2016-11 · Choi HK, Jung JA, Shon J 외 5
- Population pharmacokinetic analysis to recommend the optimal dose of udenafil in patients with mild and moderate hepatic impairment.
British journal of clinical pharmacology · 2016-08 · Kim A, Lee J, Shin D 외 4
- Development of ciclopirox nail lacquer with enhanced permeation and retention.
Archives of pharmacal research · 2016-07 · Thapa RK, Choi JY, Go TG 외 6
- Odisolane, a Novel Oxolane Derivative, and Antiangiogenic Constituents from the Fruits of Mulberry (Morus alba L.).
Journal of agricultural and food chemistry · 2016-05 · Lee SR, Park JY, Yu JS 외 6
- Chitosan-Based Film of Tyrothricin for Enhanced Antimicrobial Activity against Common Skin Pathogens Including Staphylococcus aureus.
Journal of microbiology and biotechnology · 2016-05 · Han SD, Sung HJ, Lee GH 외 3
- New ethanol extraction improves the anti-obesity effects of black tea.
Archives of pharmacal research · 2016-03 · Park B, Lee S, Lee B 외 6
- Discovery and SAR of N-(1-((substituted piperidin-4-yl)methyl)-3-methoxypiperidin-4-yl)-2-methoxybenzamide derivatives: 5-Hydroxytryptamine receptor 4 agonist as a potent prokinetic agent.
European journal of medicinal chemistry · 2016-02 · Park JS, Im W, Choi S 외 7
- Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects.
Drug design, development and therapy · 2016-01 · Rhee SJ, Choi Y, Lee S 외 5
- Formulation and in vivo evaluation of probiotics-encapsulated pellets with hydroxypropyl methylcellulose acetate succinate (HPMCAS).
Carbohydrate polymers · 2016-01 · Park HJ, Lee GH, Jun JH 외 4
- Hepatic role in an early glucose-lowering effect by a novel dipeptidyl peptidase 4 inhibitor, evogliptin, in a rodent model of type 2 diabetes.
European journal of pharmacology · 2016-01 · Kim TH, Kim MK, Cheong YH 외 7
- In Vitro Metabolic Pathways of the New Anti-Diabetic Drug Evogliptin in Human Liver Preparations.
Molecules (Basel, Switzerland) · 2015-12 · Jeong HU, Kim JH, Lee DY 외 2
- In vitro activity of tedizolid against gram-positive bacteria in patients with skin and skin structure infections and hospital-acquired pneumonia: a Korean multicenter study.
Annals of laboratory medicine · 2015-09 · Lee Y, Hong SK, Choi S 외 3
- Development of megestrol acetate solid dispersion nanoparticles for enhanced oral delivery by using a supercritical antisolvent process.
Drug design, development and therapy · 2015-01 · Ha ES, Kim JS, Baek IH 외 4
- Comparative safety evaluation of selective androgen receptor modulators and anabolic androgenic steroids.
Expert opinion on drug safety · 2015-01 · Choi SM, Lee BM
- Bioequivalence evaluation of two amlodipine salts, besylate and orotate, each in a fixed-dose combination with olmesartan in healthy subjects.
Drug design, development and therapy · 2015-01 · Lee SY, Kim JR, Jung JA 외 3
- Proteomic analysis of INS-1 rat insulinoma cells: ER stress effects and the protective role of exenatide, a GLP-1 receptor agonist.
PloS one · 2015-01 · Kim MK, Cho JH, Lee JJ 외 2
- Pharmacokinetic interaction between udenafil and dapoxetine: a randomized, open-labeled crossover study in healthy male volunteers.
Drug design, development and therapy · 2015-01 · Kim YH, Choi HY, Lee SH 외 4
- Evaluation of antimicrobial effects of commercial mouthwashes utilized in South Korea.
BMB reports · 2015-01 · Yang SJ, Han SH, Lee AR 외 5
- Pharmacological profile of DA-6886, a novel 5-HT4 receptor agonist to accelerate colonic motor activity in mice.
European journal of pharmacology · 2014-07 · Lee MJ, Cho KH, Park HM 외 3
- Effect of DA-9701 on colorectal distension-induced visceral hypersensitivity in a rat model.
Gut and liver · 2014-07 · Kim ER, Min BH, Lee TH 외 2
- Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers.
Drug design, development and therapy · 2014-01 · Gu N, Park MK, Kim TE 외 7
- DA-9701: A New Multi-Acting Drug for the Treatment of Functional Dyspepsia.
Biomolecules & therapeutics · 2013-05 · Kwon YS, Son M
- Differential protective effects of exenatide, an agonist of GLP-1 receptor and Piragliatin, a glucokinase activator in beta cell response to streptozotocin-induced and endoplasmic reticulum stresses.
PloS one · 2013-01 · Kim MK, Cho JH, Lee JJ 외 3
Patents
KIPRIS · applicant-matched- Subsidiary: 동아참메드내시경 소독 장치
Registered · 2025-10 · Application 1020250147042
PCT · Published · 2025-07 · Application PCT/KR2025/011093
- Subsidiary: 에코윈COMPOSITION FOR CONTROLLING ROOT KNOT NEMATODES
PCT · Published · 2025-06 · Application PCT/KR2025/007673
PCT · Published · 2025-06 · Application PCT/KR2025/007541
PCT · Published · 2025-06 · Application PCT/KR2025/007537
CN · Published · 2024-11 · Application 202480077255.X
PCT · Published · 2024-11 · Application PCT/IB2024/060898
PCT · Published · 2024-10 · Application PCT/IB2024/060467
Published · 2024-10 · Application 1020267016644
Published · 2024-09 · Application 1020240126208
Show 275 more patents
Published · 2024-09 · Application 1020240122655
- Subsidiary: 에코윈뿌리혹선충 방제용 조성물
Registered · 2024-07 · Application 1020240088570
Published · 2024-06 · Application 1020240072704
Published · 2024-06 · Application 1020240072574
PCT · Published · 2024-03 · Application PCT/KR2024/095513
- Subsidiary: 에코윈방선균용 배지 조성물
Published · 2024-01 · Application 1020240000160
CN · Published · 2023-10 · Application 202380088238.1
CN · Published · 2023-10 · Application 202380087004.5
PCT · Published · 2023-10 · Application PCT/IB2023/060602
PCT · Published · 2023-10 · Application PCT/IB2023/060601
US · Published · 2023-10 · Application 19122199
EP · Published · 2023-10 · Application 23879323.6
EP · Published · 2023-10 · Application 23879322.8
Published · 2023-10 · Application 1020257016630
Published · 2023-10 · Application 1020257016629
TW · Registered · 2023-10 · Application 112139992
TW · Registered · 2023-10 · Application 112139973
- Subsidiary: 앱티스(주)항체-킬레이터 콘쥬게이트
Rejected · 2023-09 · Application 1020230128079
Published · 2023-09 · Application 1020230121461
Published · 2023-09 · Application 1020230118636
- Subsidiary: 앱티스(주)위치특이적 항체 콘쥬게이션 및 이의 구체예로서의 항체-약물 콘쥬게이트
Published · 2023-07 · Application 1020230099296
CN · Published · 2023-07 · Application 202380048587.0
PCT · Published · 2023-07 · Application PCT/IB2023/056916
EP · Published · 2023-07 · Application 23835026.8
Published · 2023-07 · Application 1020257003624
US · Published · 2023-04 · Application 18861369
EP · Published · 2023-04 · Application 23795766.7
PCT · Published · 2023-04 · Application PCT/IB2023/054410
Published · 2023-04 · Application 1020247039878
Published · 2023-03 · Application 1020230035275
CN · Published · 2022-09 · Application 202280059950.4
PCT · Published · 2022-09 · Application PCT/KR2022/013084
US · Published · 2022-09 · Application 18688439
EP · Registered · 2022-09 · Application 22865059.4
- Subsidiary: 동아참메드빛 반사 개선 구조를 갖는 내시경용 카메라 모듈
Published · 2022-08 · Application 1020220107169
PCT · Published · 2022-08 · Application PCT/KR2022/012670
EP · Registered · 2022-08 · Application 22853489.7
PCT · Published · 2022-07 · Application PCT/KR2022/009965
Registered · 2022-07 · Application 1020220084257
Rejected · 2021-09 · Application 1020210126085
Registered · 2021-09 · Application 1020210116832
US · Registered · 2021-08 · Application 17410697
PCT · Published · 2021-06 · Application PCT/KR2021/008208
Published · 2021-06 · Application 1020210073866
CN · Published · 2021-05 · Application 202180034892.5
EP · Registered · 2021-05 · Application 21805158.9
PCT · Published · 2021-05 · Application PCT/KR2021/005930
CN · Published · 2021-04 · Application 202180028538.1
US · Published · 2021-04 · Application 17906745
EP · Published · 2021-04 · Application 21789177.9
PCT · Published · 2021-04 · Application PCT/KR2021/004904
Published · 2021-04 · Application 1020267030630
Rejected · 2021-04 · Application 1020227037505
PCT · Published · 2021-04 · Application PCT/KR2021/004747
US · Published · 2021-04 · Application 17997252
EP · Published · 2021-04 · Application 21797724.8
Published · 2021-04 · Application 1020210046734
CN · Published · 2021-03 · Application 202180024853.7
EP · Published · 2021-03 · Application 21776706.0
PCT · Published · 2021-03 · Application PCT/KR2021/003883
Registered · 2021-03 · Application 1020227037504
Published · 2021-03 · Application 1020257034039
CN · Published · 2021-03 · Application 202180019128.0
CN · Published · 2021-03 · Application 202180019079.0
EP · Published · 2021-03 · Application 21768861.3
EP · Published · 2021-03 · Application 21768185.7
PCT · Published · 2021-03 · Application PCT/KR2021/002990
PCT · Published · 2021-03 · Application PCT/KR2021/002989
Registered · 2021-03 · Application 1020210031530
Registered · 2021-03 · Application 1020210031531
Published · 2021-02 · Application 1020210023802
PCT · Published · 2020-11 · Application PCT/KR2020/016567
Rejected · 2020-11 · Application 1020200151205
Registered · 2020-10 · Application 1020200137688
US · Published · 2020-09 · Application 17039120
Registered · 2020-09 · Application 1020200117471
Registered · 2020-07 · Application 1020200081133
US · Published · 2020-06 · Application 16895816
US · Published · 2020-06 · Application 16893208
Withdrawn · 2020-05 · Application 1020200064423
Registered · 2020-05 · Application 1020200057402
Registered · 2020-04 · Application 1020200052923
Registered · 2020-03 · Application 1020200039264
- Subsidiary: 앱티스(주)위치특이적 항체 콘쥬게이션 및 이의 구체예로서의 항체-약물 콘쥬게이트
Registered · 2020-03 · Application 1020200029224
PCT · Published · 2019-09 · Application PCT/KR2019/012300
Registered · 2019-09 · Application 1020190116416
CN · Published · 2019-09 · Application 202510689612.4
CN · Published · 2019-09 · Application 201980059145.X
US · Registered · 2019-09 · Application 17275555
EP · Registered · 2019-09 · Application 19860397.9
PCT · Published · 2019-09 · Application PCT/KR2019/011839
Registered · 2019-09 · Application 1020190112561
CN · Published · 2019-09 · Application 201980083837.8
US · Registered · 2019-09 · Application 17416930
EP · Registered · 2019-09 · Application 19897865.2
PCT · Published · 2019-09 · Application PCT/KR2019/011483
- Subsidiary: 동아참메드스트로브스코프용 카메라의 불량 검출 시스템
Registered · 2019-05 · Application 1020190055267
- Subsidiary: 동아참메드스트로보스코피 카메라의 불량 감지장치
Registered · 2019-05 · Application 1020190055260
- Subsidiary: 에코윈INSECT PATHOGENIC MICROORGANISM-CONTAINING AGRICULTURAL PESTICIDE FORMULATION AND MANUFACTURING METHOD THEREFOR
PCT · Published · 2019-04 · Application PCT/KR2019/005139
Registered · 2018-12 · Application 1020180167289
Withdrawn · 2018-11 · Application 1020180136694
CN · Published · 2018-11 · Application 201880084013.8
EP · Registered · 2018-11 · Application 18896586.7
- Subsidiary: 동아참메드하이브리드 의료용 스프레이
Registered · 2018-11 · Application 1020180133514
Rejected · 2018-08 · Application 1020180098162
CN · Published · 2018-08 · Application 202410003809.3
CN · Published · 2018-08 · Application 202310958807.5
CN · Published · 2018-08 · Application 201880053473.4
US · Registered · 2018-08 · Application 16638970
EP · Published · 2018-08 · Application 22170622.9
EP · Registered · 2018-08 · Application 18846196.6
Registered · 2018-08 · Application 1020180095717
- Subsidiary: 에코윈포토랍두스 템페라타 템프라타 유래 안트라퀴논 화합물을 포함하는 뿌리혹선충 방제용 조성물
Registered · 2018-07 · Application 1020180087878
- Subsidiary: 에코윈곤충 병원성 미생물 농약제제 및 이의 제조방법
Registered · 2018-04 · Application 1020180049556
- Subsidiary: 앱티스(주)단일사슬항체조각과 바이러스 외피 단백질을 포함하는 융합단백질 및 이의 용도
Rejected · 2018-04 · Application 1020180049343
- Subsidiary: 에코윈제노랍두스 네마토필라 유래 살선충능을 갖는 화합물 및 이의 분리방법
Registered · 2018-03 · Application 1020180025929
Registered · 2018-02 · Application 1020180022252
US · Registered · 2018-02 · Application 16492780
EP · Published · 2018-02 · Application 18772434.9
PCT · Published · 2018-02 · Application PCT/KR2018/001711
Withdrawn · 2018-01 · Application 1020180009011
Registered · 2017-12 · Application 1020170180647
CN · Published · 2017-12 · Application 201780086238.2
US · Published · 2017-12 · Application 16471200
EP · Published · 2017-12 · Application 17883777.9
Rejected · 2017-12 · Application 1020170176160
Registered · 2017-12 · Application 1020170170341
PCT · Published · 2017-11 · Application PCT/KR2017/012312
CN · Published · 2017-09 · Application 201780059711.8
US · Registered · 2017-09 · Application 15718474
EP · Registered · 2017-09 · Application 17856810.1
Registered · 2017-09 · Application 1020197012063
- Subsidiary: 동아참메드토탈 셔터 이미지 센서를 이용하는 스트로보스코프
Registered · 2017-09 · Application 1020170124072
- Subsidiary: 동아참메드스트로보스코프 상에서 토탈 셔터 이미지 센서 모듈 제어를 위한 ISP
Registered · 2017-09 · Application 1020170124086
- Subsidiary: 동아참메드스트로보스코프를 위한 토탈 셔터 이미지 센서 모듈
Rejected · 2017-09 · Application 1020170124101
- Subsidiary: 동아참메드후두 스트로보스코피 및 그 촬영 방법
Registered · 2017-09 · Application 1020170124115
- Subsidiary: 앱티스(주)높은 항체결합용량과 온화한 용출 조건을 가진 항체정제용 흡착 리간드 및 그 용도
Registered · 2017-05 · Application 1020170065171
- Subsidiary: 앱티스(주)코엔자임 Q10 가용화 조성물 및 이의 제조방법
Registered · 2017-04 · Application 1020170049881
Rejected · 2017-04 · Application 1020170050047
Registered · 2017-03 · Application 1020170035623
US · Registered · 2017-03 · Application 15453511
Registered · 2017-02 · Application 1020170025184
Withdrawn · 2017-02 · Application 1020170021381
Expired · 2016-12 · Application 1020160166661
PCT · Published · 2016-08 · Application PCT/KR2016/009544
Registered · 2016-08 · Application 1020160108827
Withdrawn · 2016-05 · Application 1020160067312
Expired · 2016-04 · Application 1020160046404
Registered · 2016-03 · Application 1020160037041
US · Published · 2016-03 · Application 15554468
Registered · 2016-02 · Application 1020160024538
PCT · Published · 2016-01 · Application PCT/KR2016/000102
PCT · Published · 2016-01 · Application PCT/KR2016/000069
Expired · 2016-01 · Application 1020160000552
CN · Published · 2015-12 · Application 202110519226.2
CN · Published · 2015-12 · Application 201580069209.6
CN · Published · 2015-12 · Application 201580069243.3
Withdrawn · 2015-11 · Application 1020150159220
PCT · Published · 2015-11 · Application PCT/KR2015/011905
US · Published · 2015-11 · Application 15527246
EP · Published · 2015-11 · Application 15860147.6
EP · Registered · 2015-10 · Application 15853996.5
Expired · 2015-10 · Application 1020177014472
CN · Published · 2015-09 · Application 201580050749.X
EP · Registered · 2015-09 · Application 15842648.6
PCT · Published · 2015-09 · Application PCT/KR2015/009717
Registered · 2015-09 · Application 1020150130107
CN · Published · 2015-07 · Application 201580055671.0
US · Registered · 2015-07 · Application 15521090
EP · Registered · 2015-07 · Application 15854218.3
Registered · 2015-06 · Application 1020150090708
Rejected · 2015-05 · Application 1020150076435
Rejected · 2015-05 · Application 1020150063804
Registered · 2015-04 · Application 1020150051766
US · Registered · 2015-04 · Application 15305929
EP · Registered · 2015-04 · Application 15782235.4
PCT · Published · 2015-04 · Application PCT/KR2015/003477
Registered · 2015-03 · Application 1020150032999
Withdrawn · 2015-03 · Application 1020150032656
- Subsidiary: 동아참메드유니버셜 타입 광케이블 홀더 및 이를 포함하는 광케이블 접속장치
Registered · 2015-03 · Application 1020150029703
- Subsidiary: 동아참메드핸드피스 거치 감응형 광원 온/오프 스위치 유닛을 갖는 엔드스코프 시스템
Registered · 2015-03 · Application 1020150029694
- Subsidiary: 동아참메드광원 수냉식 엔드스코프 시스템
Rejected · 2015-03 · Application 1020150029708
Expired · 2015-02 · Application 1020150026453
Registered · 2015-01 · Application 1020150006910
Registered · 2014-12 · Application 1020140184854
Registered · 2014-12 · Application 1020140184853
Registered · 2014-11 · Application 1020140160225
US · Published · 2014-08 · Application 14459161
US · Registered · 2014-07 · Application 14908006
EP · Registered · 2014-07 · Application 14831789.4
Withdrawn · 2014-07 · Application 1020140094692
Expired · 2014-07 · Application 1020140093765
CN · Published · 2014-07 · Application 201480050982.3
US · Registered · 2014-07 · Application 14909096
EP · Registered · 2014-07 · Application 14831249.9
Registered · 2014-07 · Application 1020140090253
CN · Published · 2014-07 · Application 201480048839.0
US · Registered · 2014-07 · Application 14907267
EP · Registered · 2014-07 · Application 14829058.8
Expired · 2014-07 · Application 1020140087722
CN · Published · 2014-06 · Application 201480045577.2
US · Registered · 2014-06 · Application 14392160
EP · Registered · 2014-06 · Application 14817709.0
Registered · 2014-06 · Application 1020140073388
CN · Published · 2014-05 · Application 201480030403
US · Registered · 2014-05 · Application 14893813
EP · Published · 2014-05 · Application 14803672.6
US · Published · 2014-05 · Application 14897571
Registered · 2014-04 · Application 1020140049276
Registered · 2014-04 · Application 1020140049277
Registered · 2014-04 · Application 1020140049274
Registered · 2014-04 · Application 1020140049275
CN · Published · 2014-03 · Application 201480018703
US · Registered · 2014-03 · Application 14779534
Expired · 2014-03 · Application 1020140036344
Withdrawn · 2014-02 · Application 1020140022296
Withdrawn · 2014-01 · Application 1020140005685
Rejected · 2014-01 · Application 1020140005082
Rejected · 2014-01 · Application 1020140003858
CN · Published · 2013-12 · Application 201380073519
Registered · 2013-12 · Application 1020130150064
Expired · 2013-11 · Application 1020130140375
Rejected · 2013-10 · Application 1020130130946
Rejected · 2013-09 · Application 1020130114387
Withdrawn · 2013-08 · Application 1020130104246
Registered · 2013-08 · Application 1020130094320
Registered · 2013-07 · Application 1020130090175
Expired · 2013-06 · Application 1020130067792
Expired · 2013-05 · Application 1020130062413
Withdrawn · 2013-05 · Application 1020130049410
Registered · 2013-04 · Application 1020130040280
Rejected · 2013-04 · Application 1020130038504
Rejected · 2013-04 · Application 1020130038503
Expired · 2013-03 · Application 1020130033597
CN · Published · 2013-03 · Application 201380013228
US · Registered · 2013-03 · Application 14384084
Expired · 2012-11 · Application 1020120137862
CN · Published · 2012-06 · Application 201210177919
Withdrawn · 2012-06 · Application 1020120059336
- Subsidiary: 동아참메드엘이디 집광렌즈를 포함하는 집광 장치
Registered · 2012-04 · Application 1020120043224
Expired · 2012-03 · Application 1020120024588
Registered · 2011-12 · Application 1020110130767
- Subsidiary: 에코윈FORMULATION METHOD FOR ENTOMOPATHOGENIC NEMATODES
CN · Published · 2011-09 · Application 201110289244
Expired · 2011-07 · Application 1020110073130
Rejected · 2011-06 · Application 1020110056295
Withdrawn · 2011-03 · Application 1020110026747
Rejected · 2011-03 · Application 1020110025759
Registered · 2011-03 · Application 1020110023564
Registered · 2011-03 · Application 1020110023545
Rejected · 2011-02 · Application 1020110015463
- Subsidiary: 동아참메드의료용 스프레이 장치
Registered · 2011-02 · Application 1020110012094
Withdrawn · 2011-02 · Application 1020110010186
Withdrawn · 2011-02 · Application 1020110010159
- Subsidiary: 에코윈꿀벌부채명나방의 알을 이용한 포식성 천적의 사육방법
Rejected · 2010-12 · Application 1020100127982
US · Published · 2010-11 · Application 13989407
US · Published · 2010-11 · Application 13989048
- Subsidiary: 에코윈곤충병원성선충의 제형화 방법
Registered · 2010-11 · Application 1020100114026
- Subsidiary: 에코윈천적유지식물 화분의 포장용기
Registered · 2010-11 · Application 1020100110862
Withdrawn · 2009-07 · Application 1020090068286
- Subsidiary: 에코윈곤충병원성선충의 장기 보관방법 및 이에 따른 곤충병원성선충
Registered · 2009-05 · Application 1020090044869
- Subsidiary: 에코윈식물기생선충 방제용 제제 및 그 제조방법
Registered · 2009-04 · Application 1020090037265
TW · Registered · 2008-10 · Application 097217871
TW · Published · 2008-06 · Application 097123702
- Subsidiary: 에코윈Mechanical machine tool parts with artificial stone
TW · Registered · 2008-06 · Application 097211267
Expired · 2007-11 · Application 1020070120863
- Subsidiary: 동아참메드의료기구용 소독장치
Rejected · 2007-10 · Application 2020070017596
- Subsidiary: 동아참메드환부 검진용 조명장치
Registered · 2007-10 · Application 1020070109982
Registered · 2007-07 · Application 1020070068368
EP · Registered · 2007-02 · Application 10157481.2
Registered · 2006-12 · Application 1020060125230
Expired · 2006-08 · Application 1020060083017
- Subsidiary: 에코윈A multi-channel electrical-discharge machine
TW · Published · 2006-03 · Application 095108410
- Subsidiary: 에코윈A complex-frequency power supply device and method for electrical-discharge machining
TW · Registered · 2006-03 · Application 095108409
- Subsidiary: 동아참메드적외선 필터 결합장치
Expired · 2005-07 · Application 2020050021303
- Subsidiary: 에코윈아미노산 음이온-제2구리 착물을 포함하는 항암제 및 이의제조방법
Rejected · 2001-09 · Application 1020010055310
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive3
- OpenAIOAI-SearchBot176
- GoogleGoogleOther10
- PerplexityPerplexityBot9
- AnthropicClaudeBot2
- MicrosoftBingbot1
Measured since Aug 27, 2026 · 5 AI engines · last read Oct 9, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for DONG-A ST CO.,LTD and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies approved for the same productsPharma & CDMO
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
Alpha AI, founded in 1995 and KOSDAQ-listed in 2000, manufactures biocompatible metal implants and surgical instruments.
Founded in 1964 and KOSPI-listed in 1991, Shinhung manufactures and distributes dental equipment and materials.
GC Medical Science Corporation, KOSDAQ-listed since 2014, operates diagnostic reagent, blood glucose, and hemodialysis solution businesses.
KOSDAQ-listed point-of-care immunodiagnostics company supplying diagnostic cartridges and the ichroma/AFIAS instrument series.
KOSPI-listed in-vitro diagnostics company known for the STANDARD Q antigen/antibody test kits.
Founded in 1987 and listed on KOSDAQ in 2000, NanoenTek develops Lab-On-a-Chip in-vitro diagnostic devices and life science instruments.
MITECH CO.,LTD., founded in 1991 and listed on KOSDAQ in 2018, makes non-vascular stents and distributes Fujifilm endoscopy equipment.
KOSDAQ-listed IVD company producing COVID-19 and HIV point-of-care diagnostic reagents alongside rubber products and entertainment businesses.
Ahn-Gook Pharmaceutical sells the cough/expectorant drug Sinecuran and the eye-health supplement Tobicom.
Founded in 2011 and KOSDAQ-listed in 2019, Sugentech develops multiplex immunoblot, point-of-care, and digital healthcare diagnostics.
KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.
Founded in 1945, JW Pharmaceutical holds an original drug pipeline including Rivalo and Hemlibra, plus the IV nutrition product Winuf and OTC brand Hwakol.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition